2022
DOI: 10.1007/s11695-022-06091-z
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Bariatric Surgery on Albuminuria in Non-Diabetic Non-Hypertensive Patients with Severe Obesity: a Short-Term Outcome

Abstract: Background Obesity is a risk factor for chronic kidney disease and albuminuria. Despite the well-documented obesity association with diabetes mellitus and hypertension, its predisposition to albuminuria is not related to these comorbidities, and, in some times, its occurrence is independent of DM or hypertension. Purpose of the study The present study aimed to evaluate bariatric surgery effect on albuminuria in patients with severe obesity with no DM or hy… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(3 citation statements)
references
References 30 publications
1
2
0
Order By: Relevance
“…[5][6][7][8][9][10] In addition, bariatric surgery achieves remission rates ranging from 33% to 90% for diabetes, 43% to 83% for hypertension, 16% to 80% for dyslipidemia at 1-year post-surgery, and 77% to 83% for albuminuria at 6-12 months. [11][12][13][14][15] Regarding the risk of future CVD events, we recently reported a ~34% reduction in 10year atherosclerotic CVD (ASCVD) risk, in line with a 2020 review noting a 19% to 54% relative reduction in 10-year CVD risk one year after bariatric surgery. 9,16 All previous studies used well-known CVD risk models such as the Framingham Risk Score for 10-year CHD risk and the American College of Cardiology/American Heart Association (ACC/AHA) pooled cohort equations for 10-year ASCVD risk.…”
Section: Introductionsupporting
confidence: 71%
“…[5][6][7][8][9][10] In addition, bariatric surgery achieves remission rates ranging from 33% to 90% for diabetes, 43% to 83% for hypertension, 16% to 80% for dyslipidemia at 1-year post-surgery, and 77% to 83% for albuminuria at 6-12 months. [11][12][13][14][15] Regarding the risk of future CVD events, we recently reported a ~34% reduction in 10year atherosclerotic CVD (ASCVD) risk, in line with a 2020 review noting a 19% to 54% relative reduction in 10-year CVD risk one year after bariatric surgery. 9,16 All previous studies used well-known CVD risk models such as the Framingham Risk Score for 10-year CHD risk and the American College of Cardiology/American Heart Association (ACC/AHA) pooled cohort equations for 10-year ASCVD risk.…”
Section: Introductionsupporting
confidence: 71%
“…The nephroprotective effects of AOMs and SGLT2 inhibitors should be strongly considered in the management of patients with obesity, T2DM and renal failure. As with AOMs, BMS can prevent the decline in renal function by reducing proteinuria and albuminuria while improving glomerular hyperfiltration in patients with obesity and impaired renal function [ 100 , 101 ].…”
Section: Effect Of Obesity Treatment In Micro- and Macrovascular Comp...mentioning
confidence: 99%
“…Importantly, the CKD stage improved in 12.9% of the study participants, while the prevalence of albuminuria (UACR > 3.5 mg/mmol) decreased from 24.8% to 1.9% at the 1-year follow-up[ 83 ]. Fathy et al [ 84 ] also noted an astonishing albuminuria remission rate (83%) in 137 non-diabetic, non-hypertensive, severely obese subjects with albuminuria who underwent bariatric surgery. Moreover, in another study, subjects undergoing bariatric surgery had a lesser incidence of kidney disease than the control group (hazard ratio 0.46, 95%CI: 0.22-0.92)[ 85 ].…”
Section: Therapeutic Approachesmentioning
confidence: 99%